Chen Hongming 4
4 · Kala Pharmaceuticals, Inc. · Filed Feb 26, 2021
Insider Transaction Report
Form 4
Chen Hongming
Chief Scientific Officer10% Owner
Transactions
- Exercise/Conversion
Common Stock
2021-02-25$2.30/sh+47,000$108,100→ 233,515 total - Exercise/Conversion
Stock Option (right to buy)
2021-02-25−47,000→ 63,236 totalExercise: $2.30Exp: 2024-10-02→ Common Stock (47,000 underlying)
Footnotes (2)
- [F1]Includes 99,666 unvested RSUs.
- [F2]The option was fully vested.